A ground-breaking vaccination created by Japanese scientists may be able to stop or alter the progression of Alzheimer‘s disease.
The senescence-associated glycoprotein (SAGP), which is produced in inflammatory brain cells linked to Alzheimer’s, is the focus of this experimental vaccination. The immunisation increased the mice’s awareness of their surroundings and decreased inflammatory biomarkers as well as amyloid deposits.
The preliminary research findings have positive ramifications for future human Alzheimer’s treatments.
According to preliminary research presented at the American Heart Association’s Basic Cardiovascular Sciences Scientific Sessions 2023, a novel vaccine that targets inflamed brain cells linked to Alzheimer’s disease may hold the key to possibly preventing or altering the course of the disease.
The conference, which takes place in Boston from July 31 to August 3, 2023, presents the most recent findings in advances and discoveries in cardiovascular science.
A senolytic vaccine was previously created by scientists at Juntendo University Graduate School of Medicine in Tokyo, Japan, to eradicate senescent cells that express the senescence-associated glycoprotein (SAGP). This vaccine helped mice with age-related illnesses like atherosclerosis and Type 2 diabetes. Another study discovered that glial cells from persons with Alzheimer’s disease have elevated SAGP expression.
The researchers used this vaccination in mice to target SAGP-overexpressed cells to treat Alzheimer’s disease based on the findings from these experiments.
In the modern era, 50% to 70% of dementia patients globally suffer from Alzheimer’s disease. The unique vaccine test conducted in mice as part of our work suggests a potential cure or treatment for the illness. The next step is to replicate these findings in humans, according to the study’s principal investigator, Chieh-Lun Hsiao, Ph.D., a postdoctoral fellow in the cardiovascular biology and medicine department at Juntendo University Graduate School of Medicine in Tokyo.
|Read More news: Click here|